FDA approves new indication for Promacta
GlaxoSmithKline announced today that the US Food and Drug Administration (FDA) has approved PROMACTA ® for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Merck Reports Phase III Results With Vicrelis
Merck announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response ( SVR ) in patients with chronic hepatitis C virus ( HCV ) genotype 1 infection treated with VICTRELIS ( boceprevir ) in combination with PEGINTRON ( peginterferon alfa-2b ) and ribavirin (P/R).
Immune Cells Tactics: Divide and Conquer
Scientists understand the big picture of how vaccines work in the body but not all the specifics at the cellular level. Now they have discovered one more piece of the puzzle.